COVID-19, adaptative immune response and metabolic-associated liver disease.
Liver Int
; 41(11): 2560-2577, 2021 11.
Article
in English
| MEDLINE | ID: covidwho-1434779
ABSTRACT
Metabolic diseases are associated with a higher risk of a severer coronavirus disease 2019 (COVID-19) course, since fatty liver is commonly associated with metabolic disorders, fatty liver itself is considered as a major contributor to low-grade inflammation in obesity and diabetes. Recently a comprehensive term, metabolic (dysfunction) associated fatty liver disease (MAFLD), has been proposed. The hepatic inflammatory status observed in MAFLD patients is amplified in presence of severe acute respiratory syndrome coronavirus 2 infection. Intestinal dysbiosis is a powerful activator of inflammatory mediator production of liver macrophages. The intestinal microbiome plays a key role in MAFLD progression, which results in non-alcoholic steatohepatitis and liver fibrosis. Therefore, patients with metabolic disorders and COVID-19 can have a worse outcome of COVID-19. This literature review attempts to disentangle the mechanistic link of MAFLD from COVID-19 complexity and to improve knowledge on its pathophysiology.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Non-alcoholic Fatty Liver Disease
/
COVID-19
/
Metabolic Diseases
Type of study:
Prognostic study
/
Reviews
Limits:
Humans
Language:
English
Journal:
Liver Int
Journal subject:
Gastroenterology
Year:
2021
Document Type:
Article
Affiliation country:
Liv.15061
Similar
MEDLINE
...
LILACS
LIS